Company Filing History:
Years Active: 2020-2025
Title: Mathias Ferber: Innovator in T Cell Receptor Technology
Introduction
Mathias Ferber is a prominent inventor based in Paris, France. He has made significant contributions to the field of immunotherapy, particularly through his work on T cell receptors. With a total of five patents to his name, Ferber is recognized for his innovative approaches to cancer treatment.
Latest Patents
Ferber's latest patents include groundbreaking inventions in T cell receptor technology. One of his notable patents focuses on modified T cell receptor (TCR) α or β chains. This invention involves substituting an amino acid at position 44 according to the IMGT numbering to improve the pairing of desired chains. Another significant patent pertains to antigen recognizing constructs against tumor-associated antigens, specifically targeting the Preferentially Expressed Antigen of Melanoma (PRAME). This invention provides novel TCR-based molecules that are selective and specific for tumor-expressed antigens, offering potential for diagnosis, treatment, and prevention of cancerous diseases.
Career Highlights
Mathias Ferber is currently employed at Immatics Biotechnologies GmbH, where he continues to advance his research in immunotherapy. His work has positioned him as a key figure in the development of innovative cancer treatments.
Collaborations
Ferber collaborates with talented professionals in his field, including Sebastian Bunk and Dominik Maurer. These collaborations enhance the research and development of new therapeutic approaches.
Conclusion
Mathias Ferber's contributions to T cell receptor technology and immunotherapy are noteworthy. His innovative patents and collaborations reflect his commitment to advancing cancer treatment.